L1PA Stock Overview An investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Lee's Pharmaceutical Holdings Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Lee's Pharmaceutical Holdings Historical stock prices Current Share Price HK$0.16 52 Week High HK$0.18 52 Week Low HK$0.12 Beta 0.85 1 Month Change 11.97% 3 Month Change 29.27% 1 Year Change -4.22% 3 Year Change -54.57% 5 Year Change n/a Change since IPO -69.13%
Recent News & Updates
First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023) Sep 03
First half dividend of HK$0.02 announced Aug 30
Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong Aug 02
Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director Jul 02
Upcoming dividend of HK$0.01 per share May 21 See more updates
First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023) Sep 03
First half dividend of HK$0.02 announced Aug 30
Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong Aug 02
Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director Jul 02
Upcoming dividend of HK$0.01 per share May 21
Less than half of directors are independent Apr 22
Final dividend of HK$0.01 announced Mar 28
Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024 Mar 27
Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022) Mar 26
Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024 Mar 26
Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024 Mar 15
New minor risk - Market cap size Jan 17
New major risk - Share price stability Dec 06
Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023 Aug 31
First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022) Aug 31
New minor risk - Market cap size Aug 23 Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023
Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023 Aug 19
Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director May 18
Upcoming dividend of HK$0.01 per share at 1.3% yield May 18
Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021) Mar 31
Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List Jan 20
Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021) Nov 18
Less than half of directors are independent Nov 16
Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022 Nov 05
Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa Oct 27
Upcoming dividend of HK$0.01 per share Sep 01
Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022 Aug 27
Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021) Aug 27
Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022 Aug 17
Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022 Aug 16
Board Member recently bought €55k worth of stock Jul 24
Board Member recently bought €55k worth of stock Jul 06
Lee's Pharmaceutical Holdings Limited Announces That Teglutik Obtains Drug Registration Certificate Jun 22
First quarter 2022 earnings released: EPS: HK$0.035 (vs HK$0.07 in 1Q 2021) May 27
Lee's Pharmaceutical Holdings Limited's Natulan Obtains Drug Registration Certificate May 20
Upcoming dividend of HK$0.031 per share May 19
Lee's Pharmaceutical Holdings Limited to Report Q1, 2022 Results on May 26, 2022 May 17
Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020) Apr 27
Less than half of directors are independent Apr 27 Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 19, 2022 Mar 31
Full year 2021 earnings released: EPS: HK$3.38 (vs HK$0.22 in FY 2020) Mar 30 Lee's Pharmaceutical Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2021, Payable on 15 June 2022
Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations Nov 27
Lee's Pharmaceutical Holdings Limited Obtains Approval from the Center for Drug Evaluation Sep 29
Second quarter 2021 earnings released: EPS HK$3.59 (vs HK$0.097 in 2Q 2020) Aug 27 Shareholder Returns L1PA DE Pharmaceuticals DE Market 7D 0% -2.5% -2.6% 1Y -4.2% -15.6% 6.9%
See full shareholder returns
Return vs Market: L1PA underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is L1PA's price volatile compared to industry and market? L1PA volatility L1PA Average Weekly Movement 7.7% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: L1PA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: L1PA's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products primarily in the People's Republic of China. It focuses on various disease areas, including cardiovascular, woman health, paediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates through Proprietary and Generic Products; and Licensed-In Products segments.
Show more Lee's Pharmaceutical Holdings Limited Fundamentals Summary How do Lee's Pharmaceutical Holdings's earnings and revenue compare to its market cap? L1PA fundamental statistics Market cap €100.88m Earnings (TTM ) €7.77m Revenue (TTM ) €147.79m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) L1PA income statement (TTM ) Revenue HK$1.20b Cost of Revenue HK$581.63m Gross Profit HK$617.44m Other Expenses HK$554.38m Earnings HK$63.06m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) 0.11 Gross Margin 51.49% Net Profit Margin 5.26% Debt/Equity Ratio 14.2%
How did L1PA perform over the long term?
See historical performance and comparison Dividends
2.2% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 15:10 End of Day Share Price 2024/12/20 00:00 Earnings 2024/06/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lee's Pharmaceutical Holdings Limited is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Cheng 3V Capital Limited Yue-Kwong Lui BOCOM International Securities Limited Chu Wang Citigroup Inc
Show 6 more analysts 